giant cell arteritis
Summary: A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed)
- Petersen C, Francis C. Nonarteritic Jaw Claudication. J Neuroophthalmol. 2017;37:281-284 pubmed publisher..Although jaw claudication is often considered to be pathognomonic for giant cell arteritis, it has a broad differential diagnosis including both vascular and nonvascular conditions.
- de Boysson H, Liozon E, Lambert M, Dumont A, Boutemy J, Maigne G, et al. Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?. Am J Med. 2017;130:992-995 pubmed publisher..Prospective studies are required to confirm these findings. ..
- Ly K, Régent A, Molina E, Saada S, Sindou P, Le Jeunne C, et al. Neurotrophins are expressed in giant cell arteritis lesions and may contribute to vascular remodeling. Arthritis Res Ther. 2014;16:487 pubmed publisherb>Giant cell arteritis (GCA) is characterized by intimal hyperplasia leading to ischaemic manifestations that involve large vessels...
- Paskins Z, Whittle R, Sultan A, Muller S, Blagojevic Bucknall M, Helliwell T, et al. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study. BMC Med. 2018;16:4 pubmed publisher..with increased fracture risk and are the mainstay of treatment in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, fracture risk in these conditions has not been previously quantified...
- Dejaco C, Brouwer E, Mason J, Buttgereit F, Matteson E, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13:578-592 pubmed publisherThe fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases...
- Skeik N, Ostertag Hill C, Garberich R, Alden P, Alexander J, Cragg A, et al. Diagnosis, Management, and Outcome of Aortitis at a Single Center. Vasc Endovascular Surg. 2017;51:470-479 pubmed publisher..We retrospectively reviewed all patients' charts who were diagnosed with giant cell arteritis, Takayasu arteritis, or noninfectious aortitis presenting at a single center between January 1, 2009, and ..
- Papaliodis G. Ophthalmologic manifestations of systemic vasculitis. Curr Opin Ophthalmol. 2017;28:613-616 pubmed publisher..This review will provide a synopsis of the diseases with associated ocular manifestations. The implication for clinicians is to highlight recent case reports/series demonstrating the pathology. ..
- Koster M, Warrington K. Classification of large vessel vasculitis: Can we separate giant cell arteritis from Takayasu arteritis?. Presse Med. 2017;46:e205-e213 pubmed publisherThe two main variants of large vessel vasculitis include Takayasu arteritis and giant cell arteritis. While these two conditions have historically been considered different conditions, recent evidence questions whether they are a spectrum ..
- Grossman C, Barshack I, Koren Morag N, Ben Zvi I, Bornstein G. Risk factors for severe cranial ischaemic events in patients with giant cell arteritis. Clin Exp Rheumatol. 2017;35 Suppl 103:88-93 pubmedCranial ischaemic events constitute a significant component in the clinical spectrum of giant cell arteritis (GCA)...
- Schäfer V, Juche A, Ramiro S, Krause A, Schmidt W. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxford). 2017;56:1479-1483 pubmed publisher..7 and 98.8% for parietal branches and facial arteries, respectively. The intraclass correlation coefficient was between 0.87 and 0.98. IMT measurement can correctly distinguish vasculitic from normal arteries in suspected GCA. ..
- Emamifar A, Hess S, Gerke O, Hermann A, Laustrup H, Hansen P, et al. Polymyalgia rheumatica and giant cell arteritis-three challenges-consequences of the vasculitis process, osteoporosis, and malignancy: A prospective cohort study protocol. Medicine (Baltimore). 2017;96:e7297 pubmed publisherPolymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are common inflammatory conditions. The diagnosis of PMR/GCA poses many challenges since there are no specific diagnostic tests...
- Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377:317-328 pubmed publisher..Longer follow-up is necessary to determine the durability of remission and safety of tocilizumab. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT01791153 .). ..
- Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol. 2017;35 Suppl 103:102-110 pubmed..Sera were obtained from 33 Takayasu's arteritis (TAK) patients and 14 giant cell arteritis (GCA) patients, and from 60 age-matched normal controls (NCs)...
- Samson M, Bonnotte B. [From pathogenesis of giant cell arteritis to new therapeutic targets]. Rev Med Interne. 2017;38:670-678 pubmed publisherb>Giant cell arteritis (GCA) is the most common vasculitis in adults. GCA is a granulomatous large-vessel vasculitis involving the aorta and its major branches in people>50 years...
- Coeman M, De Pauw M. Large-vessel giant cell arteritis fever of unknown origin in a patient with a prosthetic valve. Acta Cardiol. 2013;68:529-30 pubmed